Bosentan (Tracleer)
Indications
Pulmonary Hypertension (see Pulmonary Hypertension , [[Pulmonary Hypertension]])
Congenital Heart Disease with L->R Shunt-Associated Pulmonary Hypertension
Connective Tissue Disease-Associated Pulmonary Hypertension
Idiopathic Pulmonary Arterial Hypertension (IPAH) (see Idiopathic Pulmonary Arterial Hypertension , [[Idiopathic Pulmonary Arterial Hypertension]])
Contraindications
Pharmacology
Metabolism
Administration
Dose Adjustment
Drug Interactions
Cyclosporine A : coadministration of cyclosporine A and bosentan markedly increases plasma bosentan concentration
Glyburide : coadministration of glyburide and bosentan may result in increased liver function tests
Adverse Effects
Cardiovascular Adverse Effects
Fluid Retention/Peripheral Edema (see Peripheral Edema , [[Peripheral Edema]])
Known effect of endothelin receptor antagonists
May occur within the first few weeks of starting bosentan
Hypotension (see Hypotension , [[Hypotension]])
Dermatologic Adverse Effects
Gastroenterologic Adverse Effects
Hematologic Adverse Effects
Anemia (see Anemia , [[Anemia]])
Immunologic Adverse Effects
Pulmonary Adverse Effects
Pulmonary Edema : may occur in patients with pulmonary veno-occlusive disease (VOD), suggesting this as an alternate diagnosis (see Pulmonary Veno-Occlusive Disease , [[Pulmonary Veno-Occlusive Disease]])
Other Adverse Effects
References
Property of Kenneth J. Serio, MD. Author is not responsible for errors in content, site is for information purposes only.